Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Eculizumab in Hemolytic PNH (SHEPHERD)
NCT00122304Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2004
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoints: Adverse Events, Labs, ECGs, Vital Signs and Hemolysis measured by LDH Area Under the Curve. Started Dec 2004; status: completed.
02
Drugs
eculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT00122304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122304.